One example of each of two approaches to the isolation of molecular hybridization probes and their use for the comparative investigation of gene expression and its control during differentiation of normal and leukaemic leukocytes is described. RNA preparations from the peripheral blood leukocytes of human leukaemias of various types were assayed for the relative adundance of the mRNA homologous with a cellular oncogene, c-myc. All types of leukaemia except chronic lymphatic leukaemia (CLL) showed varying levels of myc-related RNA; the highest concentrations occurred in cell populations in which blast cells predominated. In contrast, a recombinant plasmid (pCG14), isolated from a cDNA recombinant plasmid library that represented polyadenylated RNAs from the peripheral blood leukocytes of a chronic granulocytic leukaemia (CGL), hybridized with an mRNA whose occurrence is diagnostic of CGL leukocytes. This mRNA was also found in normal bone marrow cells; in both bone marrow and in CGL leukocytes, pCG14-homologous RNA occurs only in cells around the myelocyte stage in differentiation. It is suggested that these probes, and others for mRNAs whose occurrence is specific to a particular cell lineage and/or stage in differentiation, detect a new series of potential diagnostic markers. These might usefully supplement existing ones to provide a more detailed, objective subclassification of the leukaemias which could have important implications for diagnosis and therapy.
Introduction
There is now a considerable body of evidence to support the theory that leukaemias arise as a consequence of transformation event(s) in stem cells, that transformation of different target cells leads to different types of leukaemia even within the same cell lineage, and that the accumulated progeny cells are maturation-arrested at some point in the normal pathway of differentiation (Greaves 1981 (Greaves , 1982 . Much of this evidence comes from studies of the patterns of occurrence of differentiation-stage-specific proteins in leukaemic cells, particularly those detected by reactions with monoclonal antibodies. Phenotypic differences between cells arise, directly or indirectly, from qualitative and quantitative differences in their constituent proteins, and these differences largely reflect differences in the mRNA populations in the cells (Minty & Birnie 1981) . While many mRNA sequences are common to many types of cells, the relative abundances of some of these sequences can differ by several orders of magnitude between cells of different lineages (Hastie & Bishop 1976 , Young et al. 1976 , between normal and neoplastic cells (Jacobs & Birnie 1980 , Torelli et al. 1981 and between cells at different stages in differentiation (Minty et al. 1978 ). Thus, a study of the biogenesis of specific mRNAs in leukaemic cells is likely to give further important insights into the pathogenesis of this group of diseases, the relationships between the different types of leukaemia, and the uncoupling of the controls integrating proliferation and maturation that appears to have occurred during leukaemogenesis. Moreover, this approach has the advantage of exploiting the exquisitely sensitive and specific techniques of molecular hybridization, as well as identifying probes with which the expression of the 'Paper read to Section of Oncology, 12 October 1983. Accepted 12 January 1984 genes, and the control of this expression, can be studied directly at the level of the cell's genome.
An important question is how to select those mRNAs whose biogenesis might be particularly worth studying. There are two approaches to this. First, cloned probes for sequences homologous to the retroviral oncogenes can be used. Not only have oncogenes been implicated in neoplastic transformation of a variety of mammalian (including human) cell types (Pulciani et al. 1982 , Cooper 1982 , but also the expression of many of their normal cellular homologues occurs at various stages of differentiation in normal cells (Cooper 1982 , Duesberg 1983 . Second, a search can be made for mRNAs whose appearance is specifically linked with a cell lineage and/or a particular stage in differentiation. This approach, using libraries of recombinant plasmids which represent the polyadenylated RNAs of the peripheral blood leukocytes from patients with CGL ) and CLL (Shiosaka & Saunders 1982) , has proved efficacious. This paper describes the use of one of each of these types of probe to estimate the relative abundances of the corresponding mRNAs in the peripheral blood leukocytes of a variety of human leukaemias.
Methods
Samples of leukaemic cells were obtained from patients attending hospitals mainly in the Glasgow area. The samples were in the form of whole blood, leukophoresed buffy coat or anticoagulated blood treated with 'Lymphoprep' (Nyegaard and Co, Oslo, Norway). Red blood cells were removed by treatment with carbonate-buffered NH4Cl (Hjorth et al. 1981) .
Normal white blood cells were obtained from fresh buffy coats supplied by the Glasgow and West of Scotland Blood Transfusion Service; they were fractionated on discontinuous 'Percoll' (Pharmacia) gradients (Hjorth et al. 1981) , washed several times with phosphatebuffered saline and examined after staining with May-Grunwald and Giemsa to check for purity. Differential cell counts and diagnoses were determined in the Haematology Departments of the hospitals supplying the samples.
RNA was isolated from cells by lysing them in guanidinium thiocyanate and centrifuging the lysate over a layer of 5.7 mol/l CsCl ). Double-stranded cDNA was synthesized and a recombinant cDNA plasmid library constructed as described previously ). The procedure by which individual recombinant plasmids, including pCG14, were selected has been described ). The recombinant plasmid pMC41-3RC, which contains the 3' exon of the human c-myc gene (Dalla-Favera et al. 1982) , was kindly donated by Dr R C Gallo. Plasmid DNAs were labelled with 32P or with 3H by nick translation using a commercial nick-translation kit (Amersham International); the specific activities of the probes were about 108 counts/min/ig(2P) and 107 counts/min/pg(QH).
Relative abundances of c-myc and pCG14 RNAs were determined by a doubling-dilution RNA dot-blot method ) using 32P-labelled probes; hybridization was done as described by Thomas (1980) . Relative abundances of RNA sequences were measured by comparison with the reaction with arbitrarily chosen standard RNAs, samples of which were included in each assay. For c-myc-related RNA, the standard was RNA isolated from uninduced HL60 cells; for pCG14 RNA, the standard was RNA from the peripheral blood leukocytes of one 'classical' CGL patient. For in situ hybridization, cytocentrifuge preparations of cells were fixed, then hybridized with a 3H-labelled probe overnight, essentially as described by Harrison et al. (1974) . After having been washed extensively, the preparations were coated with Ilford K5 Nuclear Research Emulsion and stored at 4°C for up to 4 weeks; after development, the slides were stained with May-Grunwald and Giemsa.
Results
Relative abundances of an oncogene-related (myc) RNA Total cellular RNA extracted from the peripheral blood leukocytes of leukaemic patients was assayed for myc-related mRNA by hybridization with a recombinant plasmid containing a human partial c-myc gene sequence. The occurrence of myc-homologous sequences was -detected in samples from all types of leukaemia studied, with the sole exception of CLL ( Figure 1IA ). Expression of the same data in terms of the predominant cell type in the sample, as determined by differential cell counts on cytological preparations from the same samples, showed that the occurrence of myc-related mRNA in higher concentrations was correlated with high proportions of blast cells (both myeloid and lymphoid) in the leukocyte population ( Figure IB) . This suggests that myc is expressed in early cells of both lineages, but at much lower abundance (or not at all) in mature cells.
Relative abundances of a lineage-specific, differentiation-stage-specific mRNA The recombinant designated pCG14 was isolated from a recombinant plasmid library containing cDNA sequences transcribed from the more abundant polyadenylated RNAs in peripheral blood leukocytes of a patient with Ph'-positive CGL ). It was selected for further study as one of a number which reacted more strongly with RNA from leukocytes from CGLs than with that from CLL leukocytes ). The relative abundances of pCG14-homologous RNA in the peripheral blood leukocytes of leukaemic patients and normal individuals are summarized in Table 1 . These data show that pCG14 RNA is much more abundant (at least 10to 50-fold; Birnie et al. 1983) in CGL leukocytes than in any other populations of normal or leukaemic leukocytes; indeed, the occurrence of PCG14 RNA in high concentrations is sufficiently characteristic of a CGL leukocyte population to distinguish it from all other populations of leukocytes.
Hybridization of the 3H-labelled pCG14 DNA to fixed cytological preparations of CGL buffy coats showed that only a small proportion of these populations of cells contained pCG14 RNA at high enough concentrations to be detected in this way, even after prolonged exposure to the photographic emulsion (data not shown). These cells were identified by their morphology as being myeloid cells at about the myelocyte stage in differentiation. However, only about 40% of cells so identified contained sufficient pCG14 RNA to react with the labelled probe. The RNA homologous to pCG14 also occurs at high abundance in normal bone marrow (Table 1) , indicating that this mRNA is not leukaemia-specific. Hybridization of the probe with RNA from normal bone marrow cells that had been fractionated by buoyant densitygradient centrifugation, and with cytological preparations of bone marrow cells (both kindly supplied by Dr G E Francis, Royal Free Hospital, London), showed that pCG14 RNA occurs only in haemopoietic cells of the granulocyte series; moreover, its occurrence is differentiation-stage-specific since it can be detected only in cells at or about the myelocyte stage in granulopoiesis (Figure 2) . Again, however, only about 40% of the cells identified as myelocytes contained sufficient pCG14 RNA to be detected by in situ hybridization.
The protein encoded by pCG14 RNA has not been identified yet. The mRNA is small (about 650 nucleotides), coding for a polypeptide about the size of a globin chain ; however, pCG14 is not related to any globin gene. In normal human cells the gene for pCG14 is located on chromosome 8, the same chromosome as the human c-myc gene; however, there is no homology between pCG14 and myc, or any other known oncogene sequence (data not shown).
Discussion
The oncogene sequence chosen for this study is the human cellular homologue of the transforming gene of the avian myelocytomatosis virus (MC29 (Dalla-Favera et al. 1982). Human c-myc is located on chromosome 8, on the relatively small region that is translocated to chromosome 14, 2 or 22 in Burkitt's lymphoma cells (Klein 1983 ); c-myc is also translocated and rearranged in a proportion of undifferentiated, non-Burkitt's B-cell -Favera et al. 1983 ). The segments of these chromosomes that are involved in the translocation also contain immunoglobin genes (Klein 1983) . Moreover, the c-myc gene is amplified up to 30-fold in a human cell line, HL60, that was derived from a patient with acute promyelocytic leukaemia (Dalla-Favera et al. 1982) ; HL60 cells also contain relatively high concentrations of c-myc RNA (Westin et al. 1982) . These observations suggest that c-myc is involved in transforming some human haemopoietic cells. Our, as yet preliminary, data show that the highest concentrations of c-myc RNA occur in leukaemic leukocyte populations in which blast cells predominate, suggesting that the c-myc gene is expressed in early stages of differentiation of both myeloid and lymphoid cells, but not in more mature cells. This is in accord with the observation that the high level of c-myc DNA in HL60 cells rapidly decreases when these cells are induced to differentiate to granulocytes (Westin et al. 1982) . Thus, although the occurrence of high concentrations of c-myc-related RNA does not distinguish between myeloid and lymphoid cells, it may prove to be a useful marker of cells at an early stage in differentiation in either lineage. In contrast, the occurrence of high concentrations of pCG14-homologous RNA is lineagespecific in haemopoietic cells as well as being limited to a clearly-defined stage in differentiation, that is, cells at around the myelocyte stage in granulopoiesis. It is noteworthy that less than half of the cells identifiable as myelocytes by their morphology actually contain sufficient pCG14 RNA to be detected by in situ hybridization. This suggests that the occurrence of pCG14 RNA identifies a subset of myelocytes that are not otherwise recognizable, at least by the usual histochemical techniques. It is probably no more than a coincidence that the c-myc and the pCG14 genes are on the same chromosome in human cells; however, experiments are in progress to determine whether the pCG14 gene is also located on the segment that undergoes translocation in B-cell neoplasms.
Although high concentrations of pCG14 RNA distinguish populations of CGL leukocytes from other leukocyte populations, this is not because the expression of the pCG14 gene is leukaemia-specific. Rather, the occurrence of pCG14 DNA in peripheral blood luekocytes defines CGLs by virtue of the abnormal presence of significant numbers of immature cells of the granulocyte series in the peripheral blood of these patients.
The search for recombinant plasmids containing cDNAs that are homologous to mRNAs whose occurrence is lineage-specific and differentiation-stage-specific has proved fruitful; as well as pCG14, several other recombinants have already been isolated. The possession of a series of such probes for mRNAs that occur at different stages in the differentiation of myeloid cells in the granulocyte and monocyte lineages will allow us to study the pathogenesis of myeloid leukaemia and the phenomenon of maturation arrest in terms of the expression of these genes, and of the control of their expression. These probes will also allow us to seek and investigate differences between normal and leukaemic myeloid cells that may be linked with alterations in the genomic organization of the genes. In addition, a panel of such probes may prove useful in classifying leukaemias, particularly the acute myeloid leukaemias. Although it is unlikely that probes for leukaemia-specific (let alone leukaemiatype-specific) mRNAs will be unearthed, molecular hybridization probes that define a leukaemia in terms of lineage and of differentiation stage at which maturation-arrest has occurred may prove useful additions to the histological and immunological markers already available, particularly since the assay is based on entirely different criteria.
